Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Net Clinical Benefit of Edoxaban versus Apixaban in Patients with Atrial Fibrillation and Coronary Artery Disease
KCT0012323Phase 4Not yet recruiting
- Sponsor
- Daewoong Bio
- Start
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of edoxaban and apixaban in Atrial fibrillation (AFib) and coronary arteriosclerosis (2 arms), sponsored by Daewoong Bio. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
edoxabanapixaban
03
Conditions
Atrial fibrillation (AFib)coronary arteriosclerosis
Beyond the preview
Go deeper on KCT0012323.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0012323.